|Articles|October 23, 2014
US Healthcare Reform: A Pharm Exec Digest Special
Author(s)The Pharm Exec staff
This month’s special issue of Pharm Exec Global Digest looks at..
Advertisement
This month’s special issue of Pharm Exec Global Digest looks at
- Dealing with the “side effects” of Obamacare
- The “value” of Rxs under Obamacare
- The escalating cost of US oncology care
- And more…
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
2
Beyond the Molecule: The New Competitive Battlefield in Oncology
3
FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax
4
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
5